An Expanding Aging Population and Increases in Diagnosis and Drug Treatment Will Fuel Steady 4.6 Percent Annual Growth in the Chronic Obstructive Pulmonary Drug Market
BURLINGTON, Mass., Aug. 31 /PRNewswire/ – Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues finds that, through 2019, an expanding aging population and increases in diagnosis and drug treatment will fuel steady 4.6 percent annual growth in the chronic obstructive pulmonary disease (COPD) drug market.
The Pharmacor 2010 findings from the topic entitled Chronic Obstructive Pulmonary Disease reveal that the COPD drug market, which totaled nearly $8.4 billion in 2009, will reach more than $13 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. The findings also reveal that the drug-treated COPD population will increase by nearly 6 million patients over the next decade. Although two maintenance therapies currently dominate the COPD market–GlaxoSmithKline’s Advair/Seretide/Adoair and Boehringer Ingelheim/Pfizer’s Spiriva–the near-term market will become fractured owing to the launch of new agents and generic erosion of key brands.
The Pharmacor 2010 findings also reveal that the makers of lower-priced branded generics will capitalize on the loss of market exclusivity of Advair/Seretide/Adoair and Spiriva in the United States and Europe, and generic versions of these drugs will become available in Europe by 2019.
“Challenging regulatory environments, uncertain pricing and reimbursement restrictions and the loss of patent protection and/or market exclusivity for many top-selling COPD products will constrain the COPD market,” said Decision Resources Analyst Benjamin Guikema, Ph.D. “However, manufacturers of generic products will face great barriers to entering the COPD market, given the lack of clear regulatory pathways and the difficulty of creating a device that is acceptable to regulators, physicians and patients.”
The findings also reveal that the launch of fixed-dose combination inhalers containing a long-acting beta2 agonist (LABA) and a long-acting muscarinic antagonist (LAMA) will offer more potent bronchodilation than currently available treatments.
“Thought leaders hope that LABA/LAMA combinations will also be more effective than currently available treatments in reducing the frequency of COPD exacerbations,” Dr. Guikema said.
About Pharmacor 2010
The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Decision Resources, Inc. Christopher Comfort 781-296-2597 email@example.com
SOURCE Decision Resources